MORGAN STANLEY PLC/CALL/ROCHE GS/380/0.01/20.12.24 Stock

Warrant

DE000MB31ER9

Market Closed - Börse Stuttgart 14:42:12 2024-05-31 EDT
0.004 EUR -.--% Intraday chart for MORGAN STANLEY PLC/CALL/ROCHE GS/380/0.01/20.12.24
1 month-20.00%
3 months-55.56%
Date Price Change
24-05-31 0.004 -.--%
24-05-30 0.004 -.--%
24-05-29 0.004 -.--%
24-05-28 0.004 -.--%
24-05-27 0.004 -.--%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 02:42 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MB31ER
ISINDE000MB31ER9
Date issued 2023-01-31
Strike 380 CHF
Maturity 2024-12-20 (202 Days)
Parity 100 : 1
Emission price 0.09
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.054
Lowest since issue 0.002
Spread 0.036
Spread %90.00%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus